Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2013 / Cilt: 22 - Sayı: 3

Hipotansiyon, kronik böbrek yetmezlikli hastada mirtazapinin etkisi

Hypotension, the ınfluence of mirtazapine in a patient with chronic renal failure

Pages
307–309
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hypotension improved after the metabolization of mirtazapine (approximately thirty-six hours).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In patients with end-stage renal disease (ESRD), depression is the most commonly identified psychiatric illness; however, its prevalence varies since it is assessed by using different methods in different studies and in different populations.
📊
Key Findings & Data:This paper is a case report of a 40 year old man with a history of renal failure who developed hypotension while receiving mirtazapine therapy.
💡
Conclusion & Impact:Hypotension improved after the metabolization of mirtazapine (approximately thirty-six hours).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In patients with end-stage renal disease (ESRD), depression is the most commonly identified psychiatric illness; however, its prevalence varies since it is assessed by using different methods in different studies and in different populations. The commonly accepted view in the treatment of depression is a combination of psychotherapy and pharmacologic treatment. Mirtazapine is an antidepressant used in the treatment of major depressive illness which affects both noradrenergic and serotonergic activity. This paper is a case report of a 40 year old man with a history of renal failure who developed hypotension while receiving mirtazapine therapy. We believe that hypotension was a conclusion of the mirtazapine in our patient and hemodialysis had no influence on hypotension. Hypotension improved after the metabolization of mirtazapine (approximately thirty-six hours).

Özet

Son dönem böbrek yetmezliği olan hastalarda depresyon en sık tanımlanan psikiyatrik hastalıktır, fakat depresyon prevalansı farklı çalışmalarda, farklı popülasyonlarda, farklı yöntemlerle değerlendirildiğinden değişiklikler göstermektedir. Depresyon tedavisinde kabul gören genel görüş tedavide psikoterapi ve ilaç tedavisinin kombinasyonu şeklindedir. Mirtazapin hem noradrenerjik hem de serotonerjik aktiviteyi etkileyen ve majör depresyon ile duygu durum hastalıklarında kullanılan anti depresan ilaçtır. Bu makalede, 40 yaşında böbrek yetmezliği öyküsü olan erkek hastada mirtazapin tedavisi sırasında gelişen hipotansiyon sunulmuştur. Düşüncemize göre, hipotansiyon mirtazapin kullanımın bir sonucu oluşmuştur ve hipotansiyon üzerine diyalizin bir etkisi yoktur. İlaç metabolize edildikten sonra hipotansiyon düzelmiştir (Yaklaşık 36. saat).

🔖

Cite This Article

YAVUZ, D., YAVUZ, R. (2022). Hipotansiyon, kronik böbrek yetmezlikli hastada mirtazapinin etkisi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 22 - Sayı: 3, 307–309. https://ajindex.com/articles/636342

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Kimmel PL, Cukor D, Cohen SD, Peterson RA: Depression in end- stage renal disease patients: A critical review. Advances in Chronic Kidney Disease 2007; 14 (4): Pages 328-334
  2. Hedayati SS, Yalamanchili V, Finkelstein FO: A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney International 2012; 81: 247-255
  3. Fraile P, Garcia-Cosmes P, Garcia T, Corbacho L, Alvarez M, Tabernero JM: Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant. Nephrol Dial Transplant 2009; 24(6): 1999-2001
  4. Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL: Screening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal Disease. CJASN 2007; 2 (6): 1332-1342
  5. Timmer CJ, Sitsen JM, Delbressine LP: Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38(6): 461-474 Frazer A: Pharmacology of antidepressants. J Clin Psychopharmacol 1997; 17: 2S-18S Stimmel GL, Sussman N, Wingard P: Mirtazapine safety and tolerability: Analysis of the clinical trials database. Primary Psychiatry 1997; 1: 82-96
  6. Bengtsson F, Höglund P, Timmer C, Hegbrant J: Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Human Psychopharmacology: Clinical and Experimental 1998; 13(5): 357-365 Störmer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28(10): 1168-1175
  7. Yalcin AU, Kudaiberdieva G, Sahin G, Gorenek B, Akcar N, Kuskus S, Bayrak F, Timuralp B: Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis- induced hypotension. Nephron Physiol 2003; 93(1): P21-28